Dr. Gill reviews the advantages and challenges of using the newly approved recombinant von WIllebrand factor replacement product in clinical practice.
Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease
Recent Articles
CMML: A Unique Overlap Syndrome Receiving Increased Attention
For many years, chronic myelomonocytic leukemia (CMML) has been treated as a form of myelodysplastic syndrome (MDS), despite its unique clinical and biological characteristics.
“Everyone...
New Treatment Options Lead to New Questions in Acute Myeloid Leukemia
For the past 40 years, the standard remission induction treatment for patients with newly diagnosed acute myeloid leukemia (AML) who are candidates for intensive...
Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL
Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...
Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS
Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...
RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML
Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...
Current Issue
April 2019, Volume 5, Issue 5
This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.
